Winette T. A. van der Graaf
Led PALETTE, the trial that made pazopanib the first targeted drug for soft-tissue sarcoma.
Overview
Winette van der Graaf was principal investigator of PALETTE, the EORTC trial showing pazopanib improves progression-free survival in pretreated non-adipocytic soft-tissue sarcoma, leading to its approval as the first targeted therapy in the disease. She chaired the EORTC Soft Tissue and Bone Sarcoma Group and leads adolescent and young adult cancer research in the Netherlands.
Pages like this
not linked directly; found by shared links- PersonWilliam D. Tap
Shares Sarcomas (soft tissue, bone, GIST), Small-molecule kinase inhibitors and the tag sarcoma.
- ProductPazopanib
Shares Anti-angiogenic therapy, VEGF / VEGFR, Sarcomas (soft tissue, bone, GIST), Small-molecule kinase inhibitors.
- CancerOsteosarcoma
Shares VEGF / VEGFR, Small-molecule kinase inhibitors and the tags sarcoma, aya.
- TrialSANET-ep and SANET-p
Shares Anti-angiogenic therapy, VEGF / VEGFR.
- PersonMartin J. van den Bent
Shares Erasmus MC Cancer Institute and the tag eortc.
- PersonGeorge D. Demetri
Shares Sarcomas (soft tissue, bone, GIST), Small-molecule kinase inhibitors and the tag sarcoma.
- CancerEwing sarcoma
Shares the tags sarcoma, aya.
- TrialSELECT
Shares Anti-angiogenic therapy, VEGF / VEGFR, Small-molecule kinase inhibitors.